Targeted triple therapy tested for Tough-to-Treat bladder cancer
NCT ID NCT05335941
Summary
This study is testing a combination of three drugs for people with advanced bladder cancer that has a specific genetic flaw called MTAP deficiency and has stopped responding to standard immunotherapy. The goal is to see if this new combination is safe and can help control the cancer. It is for adults whose cancer has spread and who have already tried immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.